Effects ofβ 2-adrenergic agonists on isolated guinea pig lung mast cells

The mast cell protective effects of the newly developed long-acting ₂-adrenergic salmeterol and formoterol were compared with those of conventionally used ₂-adrenergic, non-specific -agonists, disodium cromoglycate (DSCG) and theophylline. With the exception of DSCG, all the test agents inhibited ovalbumin-induced histamine release from enzymically dispersed guinea pig lung mast cells in a dose-dependent fashion. At the maximum concentration tested, theophylline produced the highest level of protection, inhibiting up to 90% of ovalbumin-induced histamine release whereas DSCG produced only 10% inhibition. The maximum inhibition produced by all the ₂-adrenergic tested was around 45%. While salmeterol was equipotent with salbutamol, formoterol was at least a 100-fold more potent. Hence the present study confirmed the previously reported mast cell stabilizing actions of conventional ₂-adrenergic and extended the observation to the newly developed long-acting analogues.     

钙激活的氯通道gob-5和粘蛋白基因Muc5ac在小鼠哮喘模型肺部的表达

目的：研究“钙激活的氯通道”成员之一gob-5和粘蛋白基因Muc5ac在小鼠哮喘模型肺部的表达。 方法： 22只清洁级BALB/c小鼠随机分成哮喘组和对照组，用逆转录聚合酶链反应法（RT-PCR）和免疫组化法分别测定肺组织gob-5 mRNA和粘蛋白基因Muc5ac蛋白的表达。 结果： 小鼠哮喘组肺组织gob-5 mRNA表达阳性（0.2297±0.0186，A），而对照组未出现gob-5 mRNA的表达(P<0.01)；哮喘组Muc5ac蛋白表达（0.6637±0.0127，A）明显高于对照组（0.2060±0.0179，A）（P<0.01）；哮喘组肺组织gob-5 mRNA表达与Muc5ac蛋白表达呈直线正相关（r=0.864, P<0.05）。 结论： Gob-5 mRNA表达的上调可能在哮喘小鼠气道粘液过度分泌中起着关键作用；抑制gob-5的表达将为哮喘的治疗提供新的策略。     

Pharaoh ant (Monomorium pharaonis): newly identified important inhalant allergens in bronchial asthma

The nonstinging house ant, Monomorium pharaonis (pharaoh ant), was recently identified as a cause of respiratory allergy. This study was performed to evaluate the extent of sensitization to pharaoh ant, and its clinical significance in asthmatic patients. We carried out skin prick tests in 318 patients with asthma. Specific IgE (sIgE) to pharaoh ant was measured by ELISA, and cross-reactivity was evaluated by ELISA inhibition tests. Bronchial provocation testing was performed using pharaoh ant extracts. Fifty-eight (18.2%) of 318 patients showed positive skin responses to pharaoh ant, and 25 (7.9%) had an isolated response to pharaoh ant. Positive skin responses to pharaoh ant were significantly higher among patients with non-atopic asthma than among those with atopic asthma (26.0% vs. 14.9%, p<0.05). There was significant correlation between sIgE level and skin responses to pharaoh ant (rho=0.552, p<0.001). The ELISA inhibition tests indicated that pharaoh ant allergens had various pattern of cross-reactivity to house dust mites and cockroaches. Bronchial provocation tests to pharaoh ant were conducted for 9 patients, and eight showed typical asthmatic reactions. In conclusion, pharaoh ant is an important source of aeroallergens, and it should be included in the skin test battery for screening the causative allergens in patients with asthma.     

哮喘患者痰嗜酸性粒细胞凋亡与IL-5及sIL-2R相关性的研究

目的：探讨哮喘患者痰液嗜酸性粒细胞凋亡(EOS)与IL-5和sIL-2R的关系。方法：选择哮喘患者(哮喘组)急性发作期和缓解期30例，20名健康人(正常组)作对照。分别采用ELISA法测定患者痰液白细胞介素5(IL-5)和可溶性白介素2受体(sIL-2R)，应用流式细胞仪检测痰液EOS凋亡。结果：哮喘患者急性发作期和缓解期痰液中IL-5和sIL-2R明显升高，EOS凋亡率增高，而正常组未发现EOS凋亡。急性发作期哮喘患者EOS凋亡率与IL-5呈明显的负相关，r为～0.78。结论：哮喘患者气道局部有EOS凋亡现象，并受到IL-5相互作用的调节。sIL-2R与EOS凋亡率无明显的相关性。     

卡介苗对豚鼠实验性哮喘的预防性治疗作用

目的:观察卡介苗(BCG)对哮喘豚鼠的预防治疗作用。方法:采用31只豚鼠,分为3组进行处理,分别为对照组、卵蛋白(OVA)致敏组和BCG处理组。用OVA(Ⅲ级)致敏豚鼠复制豚鼠哮喘模型。结果:本模型采用10%的OVA致敏,1%的OVA激发,所有动物都表现有不同程度的过敏反应症状。实验动物在接受BCG注射后,表现为以下特点:一是外周血淋巴细胞和单核细胞增加;二是BALF中细胞分类的变化,支气管肺泡灌洗液(BALF)中以淋巴细胞的增加最为明显。 经过OVA致敏的动物BALF和肺组织中嗜酸性粒细胞(EOS)明显增加,BCG不同程度地降低肺组织EOS的气道浸润及减轻OVA致敏豚鼠的气道反应。结论:[HTSS]使用本实验体系BCG可以减轻实验性哮喘的气道炎症反应。     

郃郎喘必消冲剂的药理研究

本文通过对小鼠急性毒性实验,抗炎实验,对胸腺脾脏的影响及对豚鼠在体、离体气管平滑肌作用实验,观察了郃郎喘必消冲剂的药理学效应。结果表明,该制剂无明显毒性,最大耐受量为1000g/kg/d。它有明显的对抗二甲苯致小鼠耳炎及延长组胺诱发哮喘发作潜伏期的作用,对豚鼠离体气管平滑肌无松驰作用,对小鼠胸腺和脾脏有使其重量减小的趋势,但与对照组比较无显著性差异。     

支气管哮喘病人焦虑与生命质量的相关性研究

目的　评估支气管哮喘病人焦虑与生命质量的水平 ;探讨支气管哮喘病人焦虑与生命质量的关系 .方法应用状态 -特质焦虑问卷 (STAIFORMY)和世界卫生组织生命质量量表简表 (WHOQOL -BREF) ,分别对支气管哮喘门诊病人和健康对照人群的焦虑和生命质量水平进行问卷调查 .结果　哮喘组状态焦虑为 45 1± 9 7,特质焦虑为46 5± 9 7,生命质量为 87 3± 13 2 ;健康组的状态焦虑为 3 7 7± 7 4,特质焦虑为 3 8 4± 8 1,生命质量为 95 4± 11 7.哮喘组状态焦虑、特质焦虑与生命质量均负相关 ,相关系数分别为 - 0 69和 - 0 79.结论　①支气管哮喘病人的状态焦虑及特质焦虑水平均高于健康人群 ,生命质量水平低于健康人群 ;②支气管喘病人的焦虑与生命质量负相关 .因此 ,在护理实践中应对哮喘病人进行焦虑的心理护理 ,提高其生命质量     

信号转导和转录激活因子6基因多态性与湖北汉族人变应性哮喘的相关性研究

目的　探讨信号转导和转录激活因子 (STAT) 6基因 3′非翻译区G2 96 4A位点多态性和第一外显子GT串联重复序列遗传多态性与湖北汉族人变应性哮喘易感性的关系。方法　用聚合酶链反应 限制性片段长度多态性 (PCR RFLP)技术检测STAT6基因G2 96 4A位点多态性 ;用聚合酶链反应 短串联重复多态性 (PCR STR)技术对STAT6基因第一外显子微卫星进行分型 ,并将PCR产物克隆及测序鉴定 ;采用病例 对照法研究了 1 35例变应性哮喘患者和 1 0 9例对照。结果　 ( 1 )湖北地区汉族人群STAT6基因G2 96 4A位点基因型以GA型最为常见 ;哮喘组与对照组STAT6基因G2 96 4A位点的等位基因频率和基因型频率GG、GA、AA之间差异无统计学意义 (P >0 .0 5)。 ( 2 )STAT6基因第一外显子微卫星多态性共检出GT串联重复次数为 1 3、1 4、1 5、1 6的 4种等位基因 ;第一外显子微卫星的多态性检测出 1 3/1 4基因型在哮喘患者组和正常对照组相比差异具有统计学意义(P =0 .0 0 1 4 )。 ( 3)STAT6基因第一外显子GT二核苷酸串联重复序列多态性中 1 3 GT重复等位基因与 2 96 4A变异体之间存在连锁不平衡 (P =0 .0 0 0 0 2 1 8)。结论　STAT6基因 3′非翻译区G2 96 4A位点多态性与湖北汉族人哮喘易感性无明显相关性 ;第一外显子GT二核苷酸串联重     

IL-13对小鼠哮喘模型气道黏蛋白基因Muc5ac及Bcl-2、Bax表达的作用

目的研究白细胞介素-13(IL-13)处理小鼠支气管哮喘(哮喘)模型前后肺组织黏蛋白基因Muc5ac、凋亡相关蛋白Bcl-2和Bax表达的作用,探讨气道黏液过度分泌的机制.方法45只雄性BALB/c小鼠随机分为对照组、哮喘组和IL-13组,每组15只.用逆转录-聚合酶链反应(RT-PCR)方法和免疫组化法分别检测Muc5acmRNA、Muc5ac蛋白、Bcl-2蛋白以及Bax蛋白在肺组织的表达.结果哮喘组和对照组肺组织Muc5acmRNA分别为(0.1552±0.0057)和(0.0633±0.0013),Muc5ac蛋白分别为(0.8849±0.0257)和(0.1166±0.0064),两组比较差异均有统计学意义(P<0.01);IL-13组肺组织Muc5acmRNA和蛋白分别为(0.2807±0.0027)和(1.6138±0.0483),与哮喘组、对照组比较差异也均有统计学意义(P均<0.01).与对照组Bcl-2蛋白(0.3279±0.0136)、Bax蛋白(1.7284±0.0263)相比,哮喘组分别增加和降低(分别为0.8383±0.0310和0.8987±0.0106),两组差异均有统计学意义(P均<0.01);IL-13处理后可分别促进Bcl-2和Bax蛋白增加和降低(分别为1.6934±0.0229和0.3522±0.0152),其和哮喘组的差异均有统计学意义(P均<0.01);哮喘组和IL-13组小鼠肺组织Muc5acmRNA、蛋白表达与Bcl-2蛋白表达均呈直线正相关(P均<0.05),而与Bax蛋白表达则均呈直线负相关(P均<0.05).结论IL-13是引起哮喘气道黏液过度分泌的重要细胞因子,它可能通过改变Bcl-2和Bax的表达导致了上述病变.     

Further studies on the chronotherapy of asthma with inhaled steroids: The effect of dosage timing on drug efficacy

Background: Chronotherapy studies with inhaled corticosteroids have shown optimal therapeutic benefit when steroids are administered four times per day (QID) or once daily at 3 PM.Objective: This study evaluated whether more convenient once-daily dosage times (8 AM and 5:30 PM) produce improvement in asthma equivalent to QID.Methods: Efficacy outcome measures included FEV₁, peak expiratory flow rates, bronchial responsiveness, use of β₂-agonists, nocturnal awakenings, and responses to a quality of life questionnaire. Systemic effects were blood eosinophil count, cortisol level, 24-hour urinary cortisol, and evaluation for oral candidiasis and dysphonia.Results: Baseline measurements for all three treatment groups were similar. For morning peak expiratory flow rate, significant improvement was seen for the QID group (p = 0.001) and the 5:30 PM group (p = 0.003), but not the 8 AM group (p = 0.75). For evening peak expiratory flow rate, significant improvement was seen for the QID group (p = 0.005) and the 5:30 PM group (p = 0.01), but not for the 8 AM group (p = 0.47). There were significant improvements in all other outcome variables for each group except PC₂₀. There was a significant improvement in PC₂₀ only in the QID group. The systemic effects of the three regimens were comparable.Conclusion: Dosing of inhaled steroid at 5:30 PM had no increased systemic effects and produced efficacy similar to QID dosing. Dosing at 8 AM did not produce results consistently comparable to QID dosing. Optimal once-daily dosing of inhaled steroid is between 3 PM and 5:30 PM.